BenchSci and Thermo Fisher Collaborate on AI-Powered Tools to Enhance R&D Productivity
ByAinvest
Wednesday, Oct 1, 2025 7:27 am ET1min read
TMO--
The partnership will enable scientists and researchers to interpret large scientific datasets, design more effective experiments, review published literature, and optimize laboratory resources. This collaboration is expected to significantly enhance the efficiency and productivity of R&D processes, potentially leading to faster and more cost-effective development of new medicines.
Liran Belenzon, CEO and co-founder of BenchSci, commented, "BenchSci’s technology acts as an AI assistant for scientists, leveraging a proprietary biomedical knowledge graph and machine learning models to decode scientific evidence and uncover biological insights. This partnership will expand what’s possible for researchers everywhere." Gianluca Pettiti, executive vice president and president, Life Sciences, Diagnostics and Applied at Thermo Fisher Scientific, added, "AI is unlocking a new era of scientific possibility, and our partnership with BenchSci will help our customers accelerate their important work."
The partnership builds on BenchSci's mission to exponentially increase the speed and quality of life-saving R&D. By combining BenchSci's AI expertise with Thermo Fisher Scientific's global scale and innovation leadership, the collaboration aims to transform the capabilities of scientists across the life sciences ecosystem.
BenchSci has partnered with Thermo Fisher Scientific to develop AI-powered tools to accelerate R&D productivity. The partnership will create enterprise software solutions for scientific instruments, advanced literature search, and optimized reagent selection. The tools will help scientists interpret data, design experiments, review literature, and optimize lab resources.
September 12, 2025 - BenchSci, a leading provider of AI solutions for preclinical research and drug discovery, has announced a strategic partnership with Thermo Fisher Scientific Inc. to develop AI-powered tools aimed at accelerating experimental design and improving research and development (R&D) productivity. The collaboration leverages BenchSci's ASCEND™ AI technology to create enterprise software solutions for scientific instruments, advanced web-based research literature search, and optimized reagent selection.The partnership will enable scientists and researchers to interpret large scientific datasets, design more effective experiments, review published literature, and optimize laboratory resources. This collaboration is expected to significantly enhance the efficiency and productivity of R&D processes, potentially leading to faster and more cost-effective development of new medicines.
Liran Belenzon, CEO and co-founder of BenchSci, commented, "BenchSci’s technology acts as an AI assistant for scientists, leveraging a proprietary biomedical knowledge graph and machine learning models to decode scientific evidence and uncover biological insights. This partnership will expand what’s possible for researchers everywhere." Gianluca Pettiti, executive vice president and president, Life Sciences, Diagnostics and Applied at Thermo Fisher Scientific, added, "AI is unlocking a new era of scientific possibility, and our partnership with BenchSci will help our customers accelerate their important work."
The partnership builds on BenchSci's mission to exponentially increase the speed and quality of life-saving R&D. By combining BenchSci's AI expertise with Thermo Fisher Scientific's global scale and innovation leadership, the collaboration aims to transform the capabilities of scientists across the life sciences ecosystem.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet